Vor Biopharma Inc. (VOR) News
Filter VOR News Items
VOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VOR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VOR News From Around the Web
Below are the latest news stories about VOR BIOPHARMA INC that investors may wish to consider to help them evaluate VOR as an investment opportunity.
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of DirectorsCAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Ho |
Vor Biopharma Secures $55.6M for Cancer Therapy TrialsThe latest announcement is out from Vor Biopharma ( (VOR) ). Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical development and extend cash runway through 2025. The transaction involves significant stakeholders, including Reid Hoffman and RA Capital Management, and is expected to bolster Vor Bio’s efforts in advancing its clinical trials for cancer therapies |
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%The funds will support clinical trials for VCAR33ALLO and trem-cel therapies in 2025. |
Vor Bio Announces $55.6 Million Private PlacementIntend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 CAMBRIDGE, Mass., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securi |
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial DesignPreliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, to |
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company UpdateCompany to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update. “We are pleased with our opera |
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial OfficerCAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company’s President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, |
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted TherapiesTrem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patient |
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company UpdateOn-track for trem-cel + Mylotarg™ and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update. “We are pleased with the progress we have made with enrollment of both the trem-cel + Mylotarg and VCAR33ALLO clinical trials during the quarter,” said Dr. Robert A |